The present study aimed to develop and characterize new formulations of dipyridamole (DP),
a pH-dependent poorly soluble drug, employing an acidic pH-modifier for improving …

… of dipyridamole rather closely fits the pharmacokinetics of an … by the use of a corresponding
pharmacokinetic model with two … of 100 mg dipyridamole in tablets varied from 37 to 66%. …

Coamorphization has been proven to be an effective approach to improve bioavailability of
poorly soluble active pharmaceutical ingredients (APIs) by virtue of solubilization, and also …

… to develop new dipyridamole (DP) formulations with acidic … Pharmacokinetic behavior of DP
was evaluated after oral … compare it with the pharmacokinetic behavior of DP in omeprazole-…

… It may be concluded that the improved pharmacological behaviour in several animal species,
the greater and more uniform bioavailability of dipyridamole after complexation, both in …

… The optimum formulation was 18% oleic acid, 12% Labrafac … assay indicated that
dipyridamole in SMEDDS dissolved … showed that dipyridamole in the SMEDDS formulation had a …

… metformin and the platelet aggregation inhibitor dipyridamole often occurs in patients with
… inhibited by dipyridamole in preclinical studies. We hypothesized that dipyridamole lowers …

… oral dipyridamole, and to render the effect of dipyridamole more … Pharmacokinetics of oral
dipyridamole(Persantin) and its … Effect of dipyridamole on human platelet behaviour. Lancet, …

… behavior. … pharmacokinetic profile of dipyridamole when data were inputted using the DRM,
while simulations from two-stage testing were most similar to the observed pharmacokinetic …

… of this study was to develop new dipyridamole (DP) salts with pH… Novel formulations of
dipyridamole with microenvironmental … pharmacokinetic behavior of dipyridamole formulation with …